NXL earnings: next report 2026-09-02, real EPS beat/miss history, analyst consensus Buy, P/E -0.98. Updated 2026-07-23.
Nexalin Technology (NXL) Research Hub
Nexalin Technology (NXL) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 4.82 USD (-4.55%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.98, market cap 0.01B. This hub links to the full technical, earnings and options research available for NXL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.82 USD (-4.55%) |
| 52-week range | 4.51 USD – 15.45 USD |
| Trend regime | Range |
| 14-day RSI | 7 (Oversold) |
| Trailing P/E | -0.98 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for NXL
Covered Call on NXL: how it works, illustrative setup around the real 4.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NXL: how it works, illustrative setup around the real 4.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NXL: how it works, illustrative setup around the real 4.82 USD price, max profit/loss, breakeven and when to use it. Educational.
NXL technical analysis: range, last 4.82 USD, RSI 7, 52w range 4.51 USD–15.45 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NXL in?
Nexalin Technology (NXL) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is NXL in an uptrend or downtrend?
As of 2026-09-11, NXL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NXL's trailing P/E ratio?
NXL's trailing P/E is -0.98, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does NXL next report earnings?
NXL is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -0.1 USD.